Suggestions
Claudio Dansky Ullmann M.D.
Chief Medical Officer. Oncology Drug Development Executive. Former National Cancer Institute Investigator
Dr. Claudio Dansky Ullmann is an experienced oncology drug development executive who was recently appointed as the Chief Medical Officer (CMO) of Context Therapeutics, a biopharmaceutical company focused on developing medicines for solid tumors.1
Professional Background
Dr. Dansky Ullmann brings over 30 years of experience in early and late-stage oncology therapeutics development to his role at Context Therapeutics.1 His career has included several notable positions:
- CMO at Avenge Bio, where he guided the clinical advancement of an allogeneic cell therapy for ovarian cancer.1
- CMO at MaxCyte, responsible for developing the CARMA™ chimeric antigen receptor (CAR) therapy program.1
- Senior Vice President and Head of Clinical Development at Infinity Pharmaceuticals, leading the development of Copiktra® through FDA approval.1
- Global Clinical Lead in the Oncology Therapy Area Unit at Takeda Pharmaceuticals.1
- Senior Investigator in the Cancer Therapy Evaluation Program at the National Cancer Institute.1
Education and Expertise
Dr. Dansky Ullmann earned his M.D. at the School of Medicine, Universidad de Buenos Aires and completed his medical oncology training at Guemes Private Hospital in Buenos Aires.1 His expertise lies in oncology and T cell therapies, with a proven track record of advancing programs through clinical development.1
Current Role
At Context Therapeutics, Dr. Dansky Ullmann will be supporting the development of the company's two clinical-stage T cell engaging assets to treat solid tumors.1 His appointment comes at a crucial time as the company advances its product candidates, CTIM-76 and CT-95, into Phase 1 clinical trials.1
Dr. Dansky Ullmann expressed excitement about joining Context Therapeutics, stating, "I am excited to join the leadership team at Context, which is focused on building an innovative portfolio of clinical stage T cell engaging bispecific therapeutics".1
Claudio Dansky Ullmann's LinkedIn profile can be found under the username claudio-dansky-ullmann-m-d-a9675968.2
